Stoke Q2 net loss $23.5M; Phase 3 EMPEROR dosed, 3-year OLE data show durability

Stoke Therapeutics, Inc.

2025-Q2 EPS reported $1.50 revenue$172,386,000

Net loss $23.5M ($0.40/sh) for Q2 2025 vs $25.7M loss in Q2 2024; H1 net income $89.4M from Biogen collaboration.
First patient dosed in global Phase 3 EMPEROR study of zorevunersen for Dravet syndrome; sites active in US, UK, Japan.
New 3-year OLE data show durable seizure reductions and continued improvements in cognition/behavior.
Phase 1 OSPREY study of STK-002 initiated for Autosomal Dominant Optic Atrophy (ADOA).
Cash $355M as of June 30, 2025, expected to fund operations to mid-2028 and into launch readiness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.